Bevacizumab In Hereditary Hemorrhagic Telangiectasia
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This research study is studying to see whether bevacizumab may treat chronic bleeding and
iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT).
Hereditary Hemorrhagic Telangiectasia (HHT) is a disorder that causes abnormal blood vessel
formation. In HHT, there is a mutation in the TGF-β pathway, which results in an increase of
vascular endothelial growth factor (VEGF) levels. An increase in VEGF levels can result in
poorly formed blood vessels that have a higher rate of bleeding than normal blood vessels.
Bevacizumab is designed to block VEGF activity. It is believed that targeting increased VEGF
levels may be able to treat HHT.
This research study involves the following study drug:
- Bevacizumab